[go: up one dir, main page]

GB201302343D0 - Pharmaceutical compositions comprising 15-OHEPA and methods for using the same - Google Patents

Pharmaceutical compositions comprising 15-OHEPA and methods for using the same

Info

Publication number
GB201302343D0
GB201302343D0 GBGB1302343.7A GB201302343A GB201302343D0 GB 201302343 D0 GB201302343 D0 GB 201302343D0 GB 201302343 A GB201302343 A GB 201302343A GB 201302343 D0 GB201302343 D0 GB 201302343D0
Authority
GB
United Kingdom
Prior art keywords
ohepa
same
pharmaceutical compositions
methods
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1302343.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DS Biopharma Ltd
Original Assignee
DS Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DS Biopharma Ltd filed Critical DS Biopharma Ltd
Publication of GB201302343D0 publication Critical patent/GB201302343D0/en
Priority to PCT/EP2013/065664 priority Critical patent/WO2014019919A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

There are disclosed pharmaceutical compositions comprising 15-OHEPA and, optionally, one or more cardiovascular agents, as well as therapeutic methods for treating various diseases and disorders using the same.
GBGB1302343.7A 2012-07-30 2013-02-11 Pharmaceutical compositions comprising 15-OHEPA and methods for using the same Ceased GB201302343D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/065664 WO2014019919A1 (en) 2012-07-30 2013-07-24 Pharmaceutical compositions comprising 15-ohepa and methods of using the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1213484.7A GB201213484D0 (en) 2012-07-30 2012-07-30 Pharmaceutical compositions comprising 15-OHEPA and methods of using the same

Publications (1)

Publication Number Publication Date
GB201302343D0 true GB201302343D0 (en) 2013-03-27

Family

ID=46881337

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1213484.7A Ceased GB201213484D0 (en) 2012-07-30 2012-07-30 Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GBGB1302343.7A Ceased GB201302343D0 (en) 2012-07-30 2013-02-11 Pharmaceutical compositions comprising 15-OHEPA and methods for using the same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB1213484.7A Ceased GB201213484D0 (en) 2012-07-30 2012-07-30 Pharmaceutical compositions comprising 15-OHEPA and methods of using the same

Country Status (2)

Country Link
GB (2) GB201213484D0 (en)
WO (1) WO2014019919A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
CN107405324A (en) * 2015-01-16 2017-11-28 艾菲穆恩有限公司 Compositions comprising 15-HEPE and methods of use thereof
WO2016181409A1 (en) 2015-05-11 2016-11-17 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome -
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
NZ744323A (en) * 2015-12-18 2020-08-28 Afimmune Ltd Compositions comprising 15-hepe and methods of using the same
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
BR112022020012A2 (en) * 2020-04-03 2022-12-13 Afimmune Ltd COMPOSITIONS COMPRISING 15-HEPE AND METHODS OF TREATMENT OR PREVENTION OF HEMATOLOGICAL DISORDERS AND/OR RELATED DISEASES
US20220133669A1 (en) * 2020-10-30 2022-05-05 Ds Biopharma Limited Pharmaceutical compositions comprising 15-hetre and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
CN1202068C (en) * 2000-02-16 2005-05-18 布里格姆及妇女医院股份有限公司 Aspirin-triggered lipid mediator

Also Published As

Publication number Publication date
GB201213484D0 (en) 2012-09-12
WO2014019919A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
IL267997A (en) Compositions, formulations and methods for treating ocular diseases
MX2020009780A (en) Autotaxin inhibitor compounds.
MX364229B (en) COMPOSITIONS and METHODS FOR TREATING CARDIOVASCULAR DISEASES.
MX2016002544A (en) Compounds useful as immunomodulators.
HK1216175A1 (en) Therapeutic compounds and compositions
PH12013502240B1 (en) Novel compounds as modulators of protein kinase
MX365294B (en) Dna-pk inhibitors.
MX2015011898A (en) Pyrazolo compounds and uses thereof.
TR201813877T4 (en) COMPOUNDS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY.
MX359327B (en) Methods and compositions for treating huntington's disease.
HK1220980A1 (en) Methods and compositions for treatment of pompe disease
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MX356755B (en) Fumigillol type compounds and methods of making and using same.
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
MX361349B (en) Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions.
MX2013013649A (en) Quinone compounds for treating ape1 mediated diseases.
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX367393B (en) ANTIFUNGAL COMPOSITIONS FOR THE TREATMENT OF SKIN and NAILS.
MX371343B (en) Liver x receptor (lxr) modulators.
MX2016002930A (en) Liver x receptor (lxr) modulators.
MX2013008559A (en) Leptin derivatives.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)
AT Applications terminated before publication under section 16(1)